INTRODUCTION
Glioblastoma multiforme (GBM) is the most common and lethal of adult brain cancers. GBM is currently treated with surgical resection, radiation, and chemotherapy (1) . Despite recent advances with multimodality interventions, the majority of patients survive less than 20 months due to tumor recurrence (2, 3) . Therefore, new therapies are needed to prevent such recurrence and improve patient survivals. Here, we report a strategy of genetic modification of T cells ("designer T cells") to redirect their killing specificity against GBM cells while leaving the normal cells of the brain unharmed.
T cells can be modified using viral or plasmid vectors to express a chimeric antigen receptor (CAR), providing a large population of patient-derived designer T cells (dTc) with the power to recognize tumor-specific antigens (4) . The CAR is a single molecule comprising an extracellular tumor-antigen binding domain, a transmembrane domain, and cytoplasmic signaling domains for T cell activation. The resulting modified T cells are redirected by the neo-specificity of the CAR to attack tumors expressing the surface antigen. T cell recognition is mediated in a major histocompatibility complex (MHC)-independent fashion, resulting in a more broadly applicable therapy that also avoids mechanisms of tumor escape via down-regulation of MHC-I that has been reported in glioblastomas (5) . Direct, loco-regional delivery of GBM-specific T cells into the surgical bed at the time of tumor resection has the potential to eradicate residual, invasive glioblastoma cells and prevent tumor recurrence. Glioma specific dTc therapy is being actively pursued in both preclinical studies and clinical trials (6) (7) (8) .
Interleukin (IL) 13 receptor Į2 (IL13RĮ2) is a GBM-associated protein that is overexpressed on virtually all GBM tumors but minimally or not at all in normal brain tissues (9, 10) . As such, IL13RĮ2 was considered suitable as a GBM-selective antigen, a rationale that has supported
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The GBM associated receptor has a moderate to high affinity for IL13 (K d = 0.25 -1.2 nM) (12) .
The widespread, normal tissue-associated receptor, IL13RĮ1, is structurally distinct, with an approximate 10-fold lower affinity for IL13 (K d = 2-30 nM) (13) (14) (15) . In the presence of IL4 receptor, however, IL13RĮ1 will form a ternary complex with IL13 (IL13RĮ1/IL13/IL4RĮ) that is of very high affinity (K d = 0.1 -0.4 nM) (13, 14) . In context with IL4RĮ, IL13RĮ1 will bind IL4 as well as IL13, but as an isolated receptor, IL13RĮ1 will bind only IL13. IL13RĮ2 is always an isolated receptor and only binds IL13.
In this study, we adapt a previously described "zetakine" approach (6) to express an IL13 CAR on dTcs to provide recognition and targeting of IL13RĮ2 on GBM tumors. Previous studies have shown that substitutions at different sites in IL13 could either enhance IL13 binding to IL13RĮ2 or block IL13 binding to IL4RĮ that generates the high affinity IL13RĮ1/IL4RĮ receptor (15) (16) (17) . Using this information, we created a novel mutant (IL13.E13K.R109K) to improve the selectively for IL13RĮ2 on GBM versus IL13RĮ1/IL4RĮ on normal tissues. Further, we incorporated a CD28 signaling domain into the CAR to provide Signal 2 co-stimulation with CD3ȗ
Signal 1 for improved dTc survival and function. Finally, we created monomeric and dimeric forms of the CAR to test hypotheses of CAR receptor binding and activation. In vitro testing and an in vivo model for intracranial loco-regional administration provide data that are encouraging for ultimate human application.
Research. NM 002188). The mutant IL13.E13K.R109K was created by PCR with mutagenic primers based on the hIL13 cDNA sequence. The transmembrane and cytoplasmic domains were amplified by PCR from hCD3ȗ cDNA clone obtained from ATCC (GenBank ID: BC025703). The human cytoplasmic CD28 chain, the hinge region of human CD8Į, and an Ig heavy chain signal sequence (VHCAMP) were amplified by PCR from pMFG-CEA (18) . Each product was digested with restriction enzymes, ligated, and amplified by PCR. Monomeric CAR was generated by mutating both Cys-29 of the CD8Į hinge and Cys-2 of CD3 transmembrane to Ala using mutagenic primers. The assembled construct was sequenced then cut and ligated into BamHI-NotI cleaved MFG retroviral expression vector.
Retrovirus Production and Genetic Modification of Primary Human T cells
Retroviral supernatants were prepared and peripheral blood T cells activated and transduced as previously (19) . Human peripheral blood mononuclear cells (PBMCs) were Ficoll-isolated from blood-filter discards (Rhode Island Blood Center, Providence, RI) then activated in the presence of OKT3 (10 μg/ml) and IL2 (300 U/ml) for 36-48 h. Cultured cells were then "spinfected" by centrifugation with retrovirus-containing supernatants plus protamine in a retronectin-coated plate for 1h at room temperature. This step was repeated two further times in the next 24 h, and then transferred to fresh RPMI-1640 medium containing 10% fetal bovine serum, antibiotics and
Author Manuscript Published OnlineFirst on September 10, 2012; DOI: 10.1158/1078-0432.CCR-12-0319 IL2 (300 IU/ml) with a 10-20-fold expansion over 1-2 weeks period. After one week in culture, cultures were >95% T cells, as used in the assays. Activated untransduced (UnTd) T cells from the same isolation were used as control group in all experiments.
Western Blot
Transduced T cells (10) were coincubated overnight with tunicamycin, an inhibitor of N-linked glycosylation, then processed to membrane fractions of protein using Mem-per Protein Extraction (Thermo-Fisher) per manufacturer's instructions, then analyzed as previously (18) . 
Flow Cytometric Analysis

Cytotoxicity Assay for Redirected Tumor Cell Killing
The cytolytic activity of T cell effectors was determined by CytoTox-GloTM Cytotoxicity Assay (Promega, Madison, WI). Effector cells were plated in 96-well plates at 37°C for 22 hours in triplicate at 5,000/well with 10,000 U251 or HUVEC target cells (E:T 0.5:1); or for 5 hours in triplicate at 50,000/well with 10,000 target cells (E:T 5:1). Figure 4 , cytokine assays did not include IL2, yielding IL2 levels in unstimulated dTc and control UnTd T cells <10 pg/ml. In this figure, results with dTc were not adjusted for CAR+ fraction (~30%).
Analysis of Cytokine Production
Proliferation and Expansion Assays
Activated T cell effectors (1 x 10) were cocultured IL2 with irradiated (7,000 rads) target cells (5 x 10) in 24-well plates in 1 ml of culture medium, supplemented with 5 IU/mL (E:T 2:1). The T cell cultures were restimulated on day 7 with fresh irradiated targets. Viable T cells were assayed by trypan blue exclusion. The starting and final CAR+ fractions were assessed by flow cytometry. Author Manuscript Published OnlineFirst on September 10, 2012; DOI: 10.1158/1078-0432.CCR-12-0319 e kt ), the impact is seen as k 2 /k 1 = log(y 2 )/log(y 1 ) in this formulation, with a log(250)/log(13) = 2.1-fold increase in the growth rate constant with antigen stimulation, comparable to values previously derived with CEA-and GD3-specific dTc (18, 27) . (For derivations, see Appendix.
Calculations of CAR+ Cell Expansions
See also Emtage et al [18] .)
We also consider the reverse method of inferring the impact of stimulation to increase dTc proliferation from the higher fraction of CAR+ cells. The relative fold-increase in dTc (y 2 /y 1 ) is 
In Vivo Efficacy Study
Six days after tumor injection, the tumor bearing-rats were randomized into 3 groups for treatment with 5 x 10 T cells (32% modification; n=13); or 5 x 10 UnTd activated T cells in 25 ȝL (n=12) at the same tumor coordinates; or no treatment (n=6). Rats were observed for systemic and neurologic toxicity, and death was recorded. At Day 120, the experiment was terminated and surviving rats were euthanized.
Magnetic Resonance Imaging
Two rats per group were selected at random for MR imaging at 1, 2, and 3 weeks following treatment, under isofluothane anesthesia. Multi-slice T2-weighted imaging with fast spin echo acquisition was acquired.
Brain Histology and Immunohistochemistry
Two rats per group selected at random were anesthetized with pentobarbital (100 mg/kg i. 
RESULTS
A central concern for any redirected cellular therapy is the specificity of the targets for tumorous versus normal expression of antigen on essential organs. The potency and accompanying potential for hazard of the dTc platform was graphically demonstrated with the death of the first patient treated with dTc expressing a CAR against Her2/neu, which has low expression in the lung, bowel and heart tissues that were targeted (20) . Accordingly, a major focus is rightly on the selectivity of the CAR for IL13RĮ2, with distribution largely restricted to GBM, versus the normal IL13RĮ1/IL4RĮ that is expressed widely in the body.
Previous studies showed that substitutions at two sites (Lys-105 and Arg-109) in IL13 could enhance IL13 binding to IL13RĮ2; while substitution at Glu-13 in IL13 could decrease IL13 binding to the IL4RĮ component of the high affinity IL13RĮ1/IL4RĮ receptor (15-17, 21, 22) .
Therefore, we designed a novel mutant IL13.E13K.R109K (Glu-13 and Arg-109 both changed to Lys) that we hypothesized would enhance selectivity for recognition of IL13RĮ2 of GBM.
Additionally, we assessed a further change to improve the potency of the dTc. The IL13RĮ2 that is expressed on glioblastomas is monomeric in structure. We speculated that monomeric CARs interacting with this monomeric receptor might allow for a tighter clustering of CAR signaling domains for improved dTc signaling and activation. Alternatively, CARs already in dimeric form might better present cytoplasmic domains for cluster-initiated signaling, increasing domain concentrations locally.
To address these hypotheses, we planned monomeric (m) and dimeric molecule and the CD3ȗ molecule. We incorporated CD28 signaling into the CAR since tumor cells do not typically express B7, the natural ligand for CD28. This 2 nd generation (gen) CAR transmits TCR signal 1 and CD28 signal 2 to resist activation-induced T cell death (AICD), providing prolonged anti-tumor effect (18, (23) (24) (25) (26) .
Creation of IL13.CD28.ȗ designer T cells
To create the dimeric wildtype (dWt) IL13.CD28.ȗ CAR, we adapted our prior MFG retroviral CD28.ȗ vector that supplies intracellular signaling components from the CD28 cytoplasmic domain and the CD3ȗ domain in a colinear design (18) (Fig.1A) . In place of the CD28 TM and ECD of our prior constructs (18, 27) , we substituted a CD3ȗ TM domain to maintain CAR dimerization without an ECD; with CD28 TM, the ECD is needed for dimerization to occur. This condensed format allowed us to study the impact of the presence or absence of an extracellular spacer on IL13 CAR expression and function.
Initial optimization studies compared the native IL13 leader with the canonical Immunoglobulin heavy chain leader employed in our other constructs (18, 27) , and compared the CAR expression with the presence or absence of a CD8a hinge domain. OKT3-activated T cells from a healthy donor were transduced with the MFG vectors to generate functional IL13.CD28.ȗ CAR+ dTc. Expression was determined by staining with anti-IL13 antibody (Fig.1B) . These tests proved critical for optimal gene expression. The heavy chain leader was much superior to the native IL13 leader for surface expression. Further, there was little surface staining without the hinge domain, suggesting poor surface transit for this CAR or steric hindrance in antibody binding from the IL13-to-membrane juxtaposition. This format with heavy chain leader plus hinge spacer was employed for all ensuing studies.
Research. (Fig.2A) . For this, we mutated the cysteines to alanine (Cys AE Ala) in the CD3ȗ TM and in the extracellular CD8Į hinge region that maintain dimerization of the CAR. As the final variation, we created a mutant IL13 (IL13.E13K.R109K) that includes alterations to improve the reactivity against IL13RĮ2+ gliomas (R109K), while reducing attack against normal tissues bearing IL13RĮ1/IL4RĮ (E13K) (22) .
When the CARs were expressed, Western blotting on non-reducing gels confirmed monomeric (~40 kDa) and dimeric (~80 kDa) products (Fig.2B) . Allowing for differences in vector supernatant titers, all formats were equally well-expressed by fluorescence intensity of surface staining on flow cytometry (Fig.2C) .
Signaling is equivalent between monomeric and dimeric CARs, but superior with mutant IL13 CARs.
To select an agent for development, we tested the aforementioned hypotheses of action in a T cell stimulation assay with IL2 secretion as read-out. Functional tests were performed with bulk modified T cells with a mixed population of CD4 and CD8 cells, reflecting current practice of clinical trials to infuse bulk modified T cells (28) that shift to inverted CD8/CD4 ratios on extended culture (27) . Four configurations were tested for signaling potential by IL2 secretion: dimeric CARs were equivalent, with no difference in signaling potential by this read-out, thus falsifying our hypothesis of a particular advantage to either the monomeric or dimeric format. In contrast, the mutant IL13 displayed characteristics that supported our hypothesis of an improved selectivity of the mutant form, with heightened signaling on the IL13RĮ2+ cell targets and reduced signaling on the IL13RĮ1+ cells. Both of the IL13 wt CARs (monomer and dimer) had signaling activity against IL13R Į1+ and Į2+ targets, as expected, with the Thp-1 Į1+ targets more potently activating the IL13 CAR+ T cells. In both of the mutant IL13 CARs, the signaling pattern was reversed, with the dTc each more potently activated by the U251 IL13R Į2+ target than by the Į1+ target. Thus, the mutant IL13 CARs were half as efficiently activated on IL13RĮ1+ Thp-1 cells and twice as efficiently activated on IL13RĮ2+ U251 cells, a four-fold improvement in selectivity.
The preferred form for development was thus mutant IL13 CAR in either monomeric or dimeric format. For the remainder of the exposition, we present data on one form (monomer mutant, mMu IL13 CAR) that was taken forward from in vitro through in vivo testing.
Functional characterization of monomer mutant (mMu) IL13.CD28.ȗ designer T cells
Insertion of mMu IL13.CD28.ȗ CAR into T cells genetically programs the resulting dTc to respond in an MHC-independent manner to IL13RĮ2+ glioblastoma cells with activation of T cell effector functions. We assayed three mechanisms relevant to antitumor activity of IL13 dTc: cytotoxicity, cytokine production and proliferation/resistance to AICD.
The single most critical feature of CAR+ T cells for antitumor therapy is their antigen-directed killing capacity. We demonstrate that IL13 CAR+ T cells recognize and kill IL13RĮ2+ glioblastoma cells (Fig. 4A ). U251 cells were 60% killed in 5 hr with an effector-to-target (E:T)
Research. (Fig. 4A left) . In a longer term assay with a lower E:T ratio of 0.5:1 (0.2:1 when adjusted for dTc fraction), 75% of targets were killed in 22 hr, showing multiple tumor cell (~3.5) killing per T cell in this interval (Fig.4A right) . Activated UnTd T cells showed negligible killing under both conditions. Cytokine production was assessed in terms of IL2 and interferon gamma (IFNȖ) released by activated dTc. IL2 is an essential growth factor for T cell survival and proliferation, and secretion of IL2 and IFNȖ has been correlated with tumor rejection (29) (30) (31) . Previous studies showed that IL2 is produced principally by CD4 helper T cells and that IFNȖ may be secreted by both CD4 and CD8 cells upon antigen engagement (31) . Bulk unfractionated IL13 dTc were cultured with target cells and supernatants assayed by ELISA. The IL13 dTc produced IL2 (confirming results of Fig.3 ) and IFNȖ when cultured with IL13RĮ2+ U251 cells but not when cultured with IL13RĮ-HUVEC cells (Fig.4B) . UnTd control T cells were negative for cytokine production on both targets. Proof of the selectively accelerated dTc growth is reflected in an enrichment of the dTc fraction by flow cytometry (Fig. 4D) . Over two weeks, the 3% starting fraction of CAR+ T cells (after background subtraction) increased to 38% (after background) on U251 targets, but remained stable (4% after background) on antigen-negative Daudi cells. This enrichment calculates to an n = 20-fold relative expansion of CAR+ T cells on stimulation versus control, corroborating the above result (n=19) (see Methods for calculations).
A single intracranial injection of mMu IL13 designer T cells increases survival in a human glioma xenograft model
To determine the in vivo antiglioma efficacy of locally injected mMu IL13 dTc, we used a human glioma xenograft model as described (32) . 1 x 10 IL13RĮ2+ U251 glioblastoma cells were stereotactically injected in the midbrain of 6 to 8 week old nude rats. On day 6 after tumor implantation (study day 0), rats were randomized into 3 groups for treatment with 5 x 10 IL13 dTc (32% modified, 80-90% viability, n=13); 5 x 10 UnTd activated T cells (>95% viability, n=12); and no treatment (n=6). T cells were injected to the tumor bed via the same stereotactic coordinates.
Two rats from each group were sacrificed at one week following T cell injections for evaluation of tumor size and T cell infiltration. H&E staining confirmed that IL13 dTc inhibited tumor growth: signs of tumor cell killing were found in rats treated with dTc but not in control animals treated
Research. (Fig. 5A) . Adjacent sections were stained with anti-CD3 antibody to determine the persistence and trafficking of T cells within the glioma; tumors were infiltrated both with UnTd activated T cells and with dTc, but with the modified T cells in much greater abundance, suggesting improved dTc persistence or tumor-induced expansion (Fig. 5A ).
Tumor volume change was followed over time by magnetic resonance imaging (MRI) (Fig. 5B) .
By MRI, no tumor was visualized in rats treated with dTc until 3 weeks following treatment. In contrast, tumors were apparent after one week and grew progressively to large size in animals that were either untreated or treated with UnTd activated T cells (Fig. 5B) .
Finally, this delayed growth of tumor on MRI was reflected in prolonged survival of the dTc treated animals. Rats that were untreated or treated with UnTd activated T cells had median survivals of 35 days (range, 35-38; n=4) and 40 days (range, 29-53; n=10), respectively (Fig. 5C , Table 1 ). The five day improved survival in the T cell treatment group was statistically significant (p = 0.025; Table 1 ), compatible with a non-specific LAK-type activity of activated T cells against tumor. In contrast, rats treated with IL3 dTc had a median survival of 88 days (range, 47-120+; n=11), with 28% surviving >120 days (p < 0.0001 vs. UnTd activated T cells; Table 1 ), indicating that the IL13 CAR confers important antitumor activity on the injected T cells.
Research. 
DISCUSSION
In this report, we describe the development and testing of designer T cells expressing a novel IL13RĮ2-directed CAR, designated mMu IL13.CD28.ȗ, as a promising therapeutic modality for GBM treatment. Following optimization tests, we obtained good expression of the CAR in normal human T cells, utilizing an immunoglobulin heavy chain leader sequence, and interposing a flexible hinge between the IL13 cytokine and the membrane. The immunoglobulin heavy chain leader was superior to the native IL13 leader, and there was little surface staining without the hinge domain. It was not distinguished whether the hinge improved surface transit or overcame a steric factor caused by membrane proximity that otherwise hampered access of antibody to its IL13 binding epitope.
The introduction of mutations in the IL13 domain improved the selectivity of the CAR for IL13RĮ2 on tumor versus the IL13RĮ1/IL4RĮ that is expressed systemically. The R109K mutation has been shown to improve the affinity of IL13 for the IL13RĮ2 receptor and the E13K mutation was shown to decrease affinity for the widespread IL13RĮ1/IL4RĮ (17, 21) . By putting these mutations together, we hoped to increase the potency of the IL13 dTc against GBM targets while decreasing the activity against the normal tissue IL13RĮ1/IL4RĮ. With IL2 response as a signaling readout, that increase was two-fold against IL13RĮ2+ cells and the decrease was two-fold against IL13RĮ1+ cells, for a four-fold swing in activity. This led to selection of the mutant for further development. Similar comparisons of activity in monomeric or dimeric formats showed no differences, and a monomeric mutated form was applied in further studies.
This IL13 dTc showed levels of cytokine production, tumor cell killing and tumor-dependent T cell expansion compatible with results seen in our other 2 nd gen dTc (18, 27) . A single
on version of the IL13 dTc versus our 2 nd gen version. They employed a single E13Y mutant versus our double mutant that employed E13K with R109K. The E13Y was selected to reduce affinity for the normal tissue IL13RĮ1/IL4RĮ, like the E13K that we employ, whereas we add the second mutation in an attempt to increase CAR affinity for the GBM receptor that could improve reactivity against tumor with lesser amounts of antigen. They, like we, also had a hinge spacer, but one (Fc) which generates solely a dimeric format (which we show is equivalent to monomeric). Finally, they applied plasmid transfer for limited duration expression instead of retroviral transfer, as in our case, that provides stable CAR expression.
In terms of cytotoxicity and IFNg production, our data parallel that of Kahlon et al (6) . We show Potential advantages in our product are the double mutant, in which the higher affinity of our second mutation is shown to improve signaling, which may be important for attacking low antigen expressing tumors; the incorporation of costimulation, which may be critical for activity in tumors lacking costimulatory ligands; and the retroviral delivery, which yields dTc with permanent modification, thus able to maintain anti-tumor surveillance for prolonged periods.
Research. The results reported here are encouraging for human application against recurrent or resected malignant gliomas, with the demonstration of sufficient power to eliminate residual tumor by intratumoral injections. Yet, some discussion is warranted regarding the selectivity of our CAR for the intended tumor target in such clinical applications. At some level, the improvement in selectivity we have shown may be deemed an advantage. However, the recognition by dTc with the mutated CAR against normal tissue IL13RĮ1 remains substantial, and no presumption of safety for normal tissues can be inferred. The consequences of an error in that assumption have the potential to be fatal, depending upon how the dTc are applied (20, 36) , and we would accordingly not propose to apply this construct systemically. An alternative, however, may be to recapitulate our model of intratumoral (or intracavitary) brain delivery of IL13 dTc in a human application, potentially arming the dTc with a suicide gene (37) to eliminate persisting dTc if leaking out of the tumor site to cause systemic or CNS toxicity. In this regard, the lack of toxicity in the rats from the IL13 dTc injection is mildly reassuring for a local delivery, in as much as human IL13 and IL13-based dTc will react with the rodent IL13RĮ1 ortholog. Alternatively, still-more-selective mutations or antibodies could be developed for a safe human clinical application; ideally, one would have a recognition domain in the CAR that is absolute for the Į2 receptor with no Į1 reactivity whatsoever. 
